Date: 2011-01-11
Type of information:
Compound: Kepivance® (palifermin). Swedish Orphan Biovitrum has acquired from Amgen the global rights for this modified version of human keratinocyte growth factor in September 2008.
Company: Swedish Orphan Biovitrum (Sweden) BL&H Co Ltd (Better Life & Health) (South Korea)
Therapeutic area: Cancer Oncology
Type agreement: Distribution
Action mechanism:
Disease: mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support
Details: The companies have signed a distribution agreement for the products Orfadin and Kepivance in South Korea Since, the South Korean Food and Drug Administration registration process is adapted to products already approved by the FDA or EMA, a registration and price reimbursement can be expected approximately one year from application. Sales on a named patient basis can be initiated already during 2011.
Financial terms:
Latest news:
